SQA Regulatory Surveillance Summary 3 | Monthly Update 2021
SQA
APRIL 30, 2021
generic, biosimilar, or hybrid application), informed consent is irrelevant provided that both applications relate to a medicinal product with the same qualitative and quantitative composition in active substances and the same pharmaceutical form. World Health Organization (WHO). Under Article 82(1) of Regulation (EC) No.
52 
Let's personalize your content